ImClone Systems Names Johnson to CEO Post

PharmaManufacturing.com
08/13/2007

ImClone Systems Inc., which develops and commercializes novel cancer therapeutics, announced on Aug. 9 that it has appointed John H. Johnson as its chief executive officer, effective August 27.

Johnson has more than two decades of executive and operational management experience in the biopharmaceutical and healthcare industries. He has held senior management positions of increasing responsibility at Johnson & Johnson (J&J) and most recently served as company group chairman of its worldwide biopharmaceuticals unit. In this executive role, Johnson was responsible for J&J's biotechnology, immunology and oncology commercial businesses, including Centocor, Ortho Biotech Products and the Worldwide Strategic Marketing Group.

Carl Icahn, chairman of the board of ImClone Systems, stated, “We look forward to working with him to take the company to the next level.”

About ImClone Systems
ImClone Systems Inc.is a fully integrated biopharmaceutical company committed to advancing oncology care by developing and commercializing a portfolio of targeted biologic treatments designed to address the medical needs of patients with a variety of cancers. The company's headquarters and research operations are located in New York City, with additional administration and manufacturing facilities in Branchburg, N.J.. For more information, visit www.imclone.com.